Medincell (XPAR:MEDCL) Change In Receivables : €-5.62 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell Change In Receivables?

Medincell's change in receivables for the quarter that ended in Sep. 2023 was €-1.50 Mil. It means Medincell's Accounts Receivable increased by €1.50 Mil from Mar. 2023 to Sep. 2023 .

Medincell's change in receivables for the fiscal year that ended in Mar. 2023 was €-5.79 Mil. It means Medincell's Accounts Receivable increased by €5.79 Mil from Mar. 2022 to Mar. 2023 .

Medincell's Accounts Receivable for the quarter that ended in Sep. 2023 was €2.05 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medincell's Days Sales Outstanding for the six months ended in Sep. 2023 was 53.64.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medincell's liquidation value for the six months ended in Sep. 2023 was €-47.92 Mil.

Medincell Change In Receivables Historical Data

The historical data trend for Medincell's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Change In Receivables Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-1.44

-0.98

-1.22

-1.39

-5.79

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Receivables	Get a 7-Day Free Trial										-2.25	0.86	-1.68	-4.11	-1.50

Medincell Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-5.62 Mil.

Medincell (XPAR:MEDCL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medincell's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.053	/	6.985	*	91
=	53.64

2. In Ben Graham's calculation of liquidation value, Medincell's accounts receivable are only considered to be worth 75% of book value:

Medincell's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	26.778	-	76.236	+	0.75 * 2.053	+	0.5 * 0
=	-47.92

Medincell Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medincell's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines